Sarepta Therapeutics Ownership | Who Owns Sarepta Therapeutics?

Overview Forecast RevenueFinancials Chart Transcripts

Sarepta Therapeutics Ownership Summary

Sarepta Therapeutics is owned by 86.45% institutional investors, 4.46% insiders, and 9.09% retail investors. Blackrock funding, inc. /de is the largest institutional shareholder, holding 12.36% of SRPT shares. iShares Core S&P Mid-Cap ETF is the top mutual fund, with 3.28% of its assets in Sarepta Therapeutics shares.

SRPT Ownership Benchmark

Type	Name	% Inst	% Insiders	% Retail
Stock	Sarepta Therapeutics	86.45%	4.46%	9.09%
Sector	Healthcare Stocks	488.17%	11.08%	-399.26%
Industry	Biotech Stocks	306.59%	11.10%	-217.69%

Institutional Shareholders

Top Institutional Shareholders by Total Shares

Holder	Shares	% Holding	Value
Blackrock funding, inc. /de	12.12M	12.36%	$207.17M
Blackrock	10.32M	10.98%	$1.63B
Vanguard group	9.09M	9.52%	$1.10B
Janus henderson group	4.33M	4.54%	$526.20M
State street	4.14M	4.41%	$654.40M
Morgan stanley	2.62M	2.79%	$414.49M
Bank of new york mellon	2.15M	2.25%	$260.87M
Wellington management group llp	2.07M	2.17%	$251.54M
Jpmorgan chase	2.02M	2.12%	$245.69M
Exome asset management	2.00M	2.04%	$1.45M

Top Institutional Shareholders by % of Total Assets

Holder	Shares	% Assets	Value
Boxer capital	650.00K	5.41%	$102.70M
Ghost tree capital	55.00K	2.72%	$8.69M
Casdin capital	990.10K	1.54%	$16.93M
Ikarian capital	449.09K	1.48%	$7.68M
Bioimpact capital	321.70K	0.95%	$5.50M
Exome asset management	2.00M	0.91%	$1.45M
683 capital management	675.00K	0.76%	$11.54M
Sphera funds management	159.32K	0.64%	$2.72M
Adar1 capital management	210.31K	0.55%	$3.60M
Jacobs levy equity management	690.41K	0.45%	$109.08M

Top Buyers

Holder	Shares	% Assets	Change
Blackrock	10.32M	0.04%	4.36M
Blackrock funding, inc. /de	12.12M	0.00%	2.21M
State street	4.14M	0.03%	2.02M
Exome asset management	2.00M	0.91%	2.00M
Morgan stanley	2.62M	0.03%	1.73M

Top Sellers

Holder	Shares	% Assets	Change
Capital investors	498.34K	0.00%	-8.56M
Avoro capital advisors	-	-	-2.67M
Farallon capital management	-	-	-2.34M
T. rowe price investment management	474.76K	0.01%	-1.52M
Groupama asset managment	-	-	-1.30M

New Positions

Holder	Shares	% Assets	Change	Value
Exome asset management	2.00M	0.91%	2.00M	$1.45M
Norges bank	1.04M	0.02%	1.04M	$126.32M
Tang capital management	420.30K	0.36%	420.30K	$7.19M
Bioimpact capital	321.70K	0.95%	321.70K	$5.50M
Quinn opportunity partners	289.72K	0.41%	289.72K	$4.95M

Sold Out

Holder	Change
Financial gravity asset management	-1.00
Harbor investment advisory	-1.00
Coppell advisory solutions	-2.00
Trust co of vermont	-2.00
Riverview trust	-3.00

Institutional Ownership Trends

Date	Holdings	Change %	Shares	Change %	Ownership	Change %	Increased Position	Change %	Decreased Position	Change %
Jun 30, 2025	410	-12.02%	84,724,983	-2.96%	86	1.07%	222	2.30%	89	-42.58%
Mar 31, 2025	23	-95.40%	6,342,126	-92.89%	6	0.07%	12	-95.02%	7	-95.39%
Dec 31, 2024	187	-62.75%	19,880,204	-77.21%	20	0.25%	88	-61.40%	54	-65.82%
Sep 30, 2024	498	-6.57%	87,082,917	-1.33%	91	1.04%	226	-23.65%	157	18.05%
Jun 30, 2024	528	18.39%	88,255,346	8.04%	93	1.24%	293	35.02%	132	4.76%

Top Mutual Funds Shareholders

Holder	Shares	% Holding	Change
iShares Core S&P Mid-Cap ETF	3.20M	3.28%	-5.78K
American Funds Growth Fund of Amer A	3.15M	3.25%	-5.26K
Capital Group Growth Fnd of Amer Comp	3.15M	3.21%	-5.26K
Vanguard Total Stock Mkt Idx Inv	2.96M	3.03%	-62.10K
Vanguard US Total Market Shares ETF	2.85M	2.94%	2.16K
American Funds AMCAP A	2.66M	2.74%	133.61K
Capital Group AMCAP Composite	2.66M	2.71%	133.61K
VA CollegeAmerica Amcap 529A	2.52M	2.64%	425.56K
Vanguard Small Cap Index	2.27M	2.32%	-6.75K
Vanguard Health Care Inv	2.11M	2.15%	307.60K

Recent Insider Transactions

Date	Name	Role	Activity	Value
Mar 12, 2025	Nicaise Claude	-	Sell	$248.20K
Dec 12, 2024	Wigzell Hans Lennart Rudolf	-	Sell	$1.31M
Dec 05, 2024	Boor Kathryn Jean	-	Sell	$205.40K
Aug 30, 2024	Estepan Ian Michael	Chief Financial Officer	Sell	$822.10K
Aug 16, 2024	Chambers Michael Andrew	-	Buy	$2.45M

Insider Transactions Trends

Date	Buy	Sell
2026 Q1	-	-
2025 Q3	-	-
2025 Q2	-	-
2025 Q1	-	1
2024 Q3	3	1

SRPT Ownership FAQ

Who Owns Sarepta Therapeutics?

Sarepta Therapeutics shareholders are primarily institutional investors at 86.45%, followed by 4.46% insiders and 9.09% retail investors. The average institutional ownership in Sarepta Therapeutics's industry, Biotech Stocks , is 306.59%, which Sarepta Therapeutics falls below.

Who owns the most shares of Sarepta Therapeutics?

Sarepta Therapeutics’s largest shareholders are Blackrock funding, inc. /de (12.12M shares, 12.36%), Blackrock (10.32M shares, 10.98%), and Vanguard group (9.09M shares, 9.52%). Together, they hold 32.87% of Sarepta Therapeutics’s total shares outstanding.

Does Blackrock own Sarepta Therapeutics?

Yes, BlackRock owns 10.98% of Sarepta Therapeutics, totaling 10.32M shares as of Jun 2024. This represents 0.04% of BlackRock's total assets, with a market value of 1.63B$. In the last quarter, BlackRock increased its holdings by 4.36M shares, a 73.22% change.

Who is Sarepta Therapeutics’s biggest shareholder by percentage of total assets invested?

Boxer capital is Sarepta Therapeutics’s biggest shareholder by percentage of total assets invested, with 5.41% of its assets in 650K Sarepta Therapeutics shares, valued at 102.7M$.

Who is the top mutual fund holder of Sarepta Therapeutics shares?

iShares Core S&P Mid-Cap ETF is the top mutual fund holder of Sarepta Therapeutics shares, with 3.28% of its total shares outstanding invested in 3.2M Sarepta Therapeutics shares.

Try Tickergate Pro Free

Customize Everything. 100% Flexibility. Fast and Easy to Use (No code or Excel Needed)

Customize your own personal stocks lists, views and charts
Choose from hundreds of fields, up to 15 years of history
Conduct deep comparison analysis

Discover trending investment themes
Find your next best investment
Research stocks using tools